オプションチェーンは、Aston Martin Lagonda Glbの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Aston Martin Lagonda Glbの市場センチメントを評価します。.

Aston Martin Lagonda Glb (OTC:AMGDF) 株価情報, オプションチェーン

Aston Martin Lagonda Global Holdings PLC is a luxury automotive manufacturer. It designs, engineers, and produces sports cars in Warwickshire, United Kingdom, and sells those models through a network of dealers. It is also involved in the servicing of sports cars, all the activities are carried out under the brand name of Aston Martin. The Group has only one operating segment, the automotive segment. The automotive segment includes all activities relating to design, development, manufacture and marketing of vehicles including consulting services; as well as the sale of parts, servicing, and automotive brand activities. Geographically, it has a presence in the United Kingdom, The Americas, the Rest of Europe, the Middle East and Africa, and the Asia Pacific region.

ASTON MARTIN LAGO NEW by Aston Martin Lagonda Global Holdings plc.

Aston Martin Lagonda Global Holdings PLC

Telsey Advisory Group analyst Sarang Vora maintains Westrock Coffee (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEST#NASDAQ">WEST</a>) with a Outperform and maintains $9 price target.

News

Price Target

Analyst Ratings

WEST

Telsey Advisory Group Maintains Outperform on Westrock Coffee, Maintains $9 Price Target

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) with a Buy and raises the price target from $73 to $75.

LEGN

HC Wainwright & Co. Maintains Buy on Legend Biotech, Raises Price Target to $75

Telsey Advisory Group analyst Dana Telsey maintains J.Jill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JILL#NYSE">JILL</a>) with a Market Perform and maintains $31 price target.

JILL

Telsey Advisory Group Maintains Market Perform on J.Jill, Maintains $31 Price Target

Guidance

Vera Bradley Sees FY26 EPS Of ($0.15) Vs. $0.1 Est.

Stifel analyst Brian Chin maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Hold and lowers the price target from $125 to $110.

Stifel Maintains Hold on Teradyne, Lowers Price Target to $110

Stock Split

NAOV

NanoVibronix Announces 1-for-11 Reverse Stock Split, Effective Mar. 14

Clene, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced new evidence from a cross-regimen, post hoc analysis of long-term survival in HEALEY ALS Platform Trial participants. The analyses further substantiate that treatment with CNM-Au8&#xAE; 30 mg delivers a significant survival benefit for people living with ALS.
New Survival Analyses The analyses compared survival in participants who received CNM-Au8 30 mg (Regimen C) to those of Regimen A in the HEALEY ALS Platform Trial. Regimen A provided a large concurrent control group vs. CNM-Au8 treatment using the same randomization criteria established within the HEALEY master protocol. Long-term survival status, determined through public records and site reporting, was evaluated over a follow-up period of up to 48 months. 78% of participants across both groups received standard ALS background therapy (riluzole, edaravone, or both) at baseline.

Biotech

General

CLNN

Clene Announced New Evidence From A Cross-Regimen, Post Hoc Analysis Of Long-Term Survival In HEALEY ALS Platform Trial Participants

Foremost Clean Energy Ltd. (NASDAQ:<a href="https://www.benzinga.com/stock/FMST#NASDAQ">FMST</a>) (CSE:<a href="https://www.benzinga.com/stock/FAT#CSE">FAT</a>) ("Foremost" or the "Company") is pleased to announce its plans for a $6.5 million exploration program in 2025 (the "Program") across its portfolio of uranium properties in the Athabasca Basin region in northern Saskatchewan. The Program includes the recently announced follow-up drill program on the Hatchet Lake Uranium Property ("Hatchet") as well as planned exploration on the Murphy Lake South, GR, Blackwing, Wolverine, and CLK properties.
&nbsp;
Following an initial evaluation of the exploration potential of the 10 properties under option from Denison Mines Corp. ("Denison")(TSX:<a class="ticker" href="https://www.benzinga.com/stock/DML#TSX">DML</a>, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNN#NYSE">DNN</a>), Foremost identified several exploration priorities for 2025. The extensive Program will include drilling, geophysical surveys, and geochemical exploration with a focus on identifying and testing discovery-ready targets across the Athabasca Basin. Utilizing systematic and disciplined testing of discovery-ready drill targets, the program is expected to also generate additional new exploration targets on several under-explored properties.

FMST

TSX:DML

Foremost Clean Energy Announces $6.5M Uranium Exploration Program Across Athabasca Basin As Well As Planned Exploration on The Murphy Lake South, GR, Blackwing, Wolverine, And CLK Properties

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Market Perform and lowers the price target from $6 to $5.

EWCZ

Telsey Advisory Group Maintains Market Perform on European Wax Center, Lowers Price Target to $5

Vera Bradley Sees FY26 Net Revenue Of $280M Vs. $398.545M Est.

NVEE

NV5 Acquires Herman Cx, Terms not Diclosed

Emergent BioSolutions Announces Agreement For Investment Into Swiss Rockets

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4381328-1&amp;h=2654247744&amp;u=http%3A%2F%2Fwww.axcelis.com%2F&amp;a=Axcelis+Technologies">Axcelis Technologies</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NASDAQ">ACLS</a>) a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced today that its Board of Directors has approved an additional $100 million in share repurchase authorization. This approval brings the current outstanding repurchase authorization to $215 million.

Buybacks

ACLS

Axcelis Announces $100M Increase To Share Repurchase Authorization; Approval Brings The Current Outstanding Repurchase Authorization To $215M

Portage Biotech Inc. ("Portage" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the resumption of patient enrollment in the fourth and final cohort of the&nbsp;dose escalation stage&nbsp;for PORT-6, a highly selective A2A antagonist, within its ADPORT-601 Phase 1b clinical trial. Portage had previously paused this trial due to funding concerns; this resumption of the trial underscores the encouraging findings observed in earlier cohorts. After the completion of the PORT-6 arm of the ADPORT-601 study, Portage will evaluate the continuation of the study into its PORT-7 (potent and selective A2B antagonist) and combination arms, on a segment-by-segment basis.
Advancing to this final dose escalation&nbsp;reaffirms Portage's confidence&nbsp;in the safety and therapeutic potential of PORT-6, bringing the Company closer to identifying an optimal dose range for further clinical development.

PRTG

Portage Biotech Resumes Enrollment In Final Cohort Of Dose Escalation For Port-6 In ADPORT-601 Trial

Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $0.07 by 528.57 percent. This is a 372.73 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $99.96 million which missed the analyst consensus estimate of $107.94 million by 7.39 percent. This is a 24.99 percent decrease over sales of $133.26 million the same period last year.

Earnings

Earnings Misses

Vera Bradley Q4 Adj $(0.30) Misses $0.07 Estimate, Sales $99.96M Miss $107.94M Estimate

Dicker Data chooses CrowdStrike to meet partner demand for the Falcon platform; CrowdStrike most requested cybersecurity solution in ANZ
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fen-us%2F&amp;esheet=54222968&amp;newsitemid=20250312968947&amp;lan=en-US&amp;anchor=CrowdStrike&amp;index=1&amp;md5=998fe634d7cc0414c8bb1b5476e69264">CrowdStrike</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) today announced a distribution agreement with Dicker Data (ASX: DDR), bringing the industry-leading <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fplatform%2F&amp;esheet=54222968&amp;newsitemid=20250312968947&amp;lan=en-US&amp;anchor=CrowdStrike+Falcon%26%23174%3B+cybersecurity+platform&amp;index=2&amp;md5=ed0e19c2155a8b1cad7682e56493c548">CrowdStrike Falcon&#xAE; cybersecurity platform</a> to Dicker Data's partners and customers across Australia and New Zealand (ANZ). This partnership expands CrowdStrike's ANZ channel ecosystem, enabling Dicker Data's partner base of leading resellers and managed service providers (MSPs/MSSPs) to drive vendor consolidation and stop breaches with the power of the Falcon platform.
Rising demand in ANZ led to Dicker Data seeking CrowdStrike given the large business opportunity presented by the Falcon platform as well as the mission-critical nature of cybersecurity. Dicker Data is committed to bringing cutting-edge cybersecurity solutions to its partner base serving enterprise, SMB and mid-market organizations across ANZ against advanced threats. With deep expertise in driving AI and cloud transformation services, Dicker Data will leverage the Falcon platform's market-defining AI capabilities, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fplatform%2Fcloud-security%2F&amp;esheet=54222968&amp;newsitemid=20250312968947&amp;lan=en-US&amp;anchor=Falcon%26%23174%3B+Cloud+Security&amp;index=3&amp;md5=d1b4d06b6e21bc41b7fa4e32fe8f3184">Falcon&#xAE; Cloud Security</a> and additional best-in-class modules, empowering partners to modernize security operations while helping customers reduce vendor costs and eliminate coverage gaps caused by fragmented security tools.

CRWD

CrowdStrike Announces New Distribution Agreement With Dicker Data To Meet Rising Cybersecurity Demand Across Australia & New Zealand Enabling Dicker Data's Partner Base Of Leading Resellers And Managed Service Providers To Drive Vendor Consolidation And Stop Breaches With The Power Of The Falcon Platform

Telsey Advisory Group analyst Dana Telsey maintains Olaplex Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>) with a Market Perform and maintains $2 price target.

OLPX

Telsey Advisory Group Maintains Market Perform on Olaplex Hldgs, Maintains $2 Price Target

Needham analyst Quinn Bolton reiterates Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) with a Buy and maintains $150 price target.

Reiteration

SLAB

Needham Reiterates Buy on Silicon Laboratories, Maintains $150 Price Target

Contracts

European Aeronautic Defence And Space Unsponsored

EADSY

RKLB

Rocket Lab To Provide 200 Solar Panels For 100 OneWeb Low Earth Orbit For Eutelsat Group

Acumen Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abos#NASDAQ">ABOS</a>), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced upcoming scientific presentations at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) in Vienna, Austria from April 1-5, 2025, and the American Academy of Neurology (AAN) Annual Meeting in San Diego, Calif., from April 5-9, 2025.
Oral presentations will focus on implementation of a validated research-use plasma pTau217 assay in the clinical trial participant screening process. Poster presentations will focus on methods of interrogating the binding of AβOs to a model of human neurons; methods to more accurately assess the AβO selectivity of nonclinical assays and sabirnetug; and early effects of sabirnetug on synaptic biomarkers in AD. Together, these presentations support the comprehensive development program for sabirnetug, which Acumen is advancing as a potential next-generation antibody treatment for early symptomatic AD.

Penny Stocks

ABOS

Acumen Pharmaceuticals Announces Upcoming Scientific Presentations On Alzheimer's Therapeutics At AD/PD In Vienna And AAN Annual Meeting In San Diego April 2025

Comments

Aston Martin Lagonda Glb

Aston Martin Lagonda Glb (AMGDF) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル